The safety of monoclonal antibodies for treatment of colorectal cancer.

Abstract:

INTRODUCTION:Monoclonal antibodies such as bevacizumab, ramucirumab, cetuximab and panitumumab play an important role in the treatment of metastatic colorectal cancer (mCRC). With the introduction of these drugs considerable improvements in both progression-free survival (PFS) and overall survival (OS) were achieved. However these antibodies are associated with a unique side effect profile. AREAS COVERED:This review provides an overview about drug efficacy of bevacizumab, cetuximab, panitumumab and ramucirumab in the treatment algorithm of mCRC. Additionally, we discuss the most common toxicites of these monoclonal antibodies. EXPERT OPINION:The most common toxicities associated with the VEGF-A directed antibody bevacizumab are hypertension, proteinuria, thromboembolism, bleeding, gastrointestinal perforation and prolonged wound healing. Similarly, the rate of hypertension and proteinuria is increased during treatment with the VEGFR2 antibody ramucirumab. On the other hand the most frequent side effects of EGFR targeted antibodies are skin rash, hypersensitivity reactions and hypomagnesemia. Due to the murine portions of cetuximab the incidence of infusion reactions is more frequent compared to panitumumab which is a pure human monoclonal antibody.

journal_name

Expert Opin Drug Saf

authors

Berger MD,Lenz HJ

doi

10.1517/14740338.2016.1167186

subject

Has Abstract

pub_date

2016-06-01 00:00:00

pages

799-808

issue

6

eissn

1474-0338

issn

1744-764X

journal_volume

15

pub_type

杂志文章,评审
  • Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901.

    abstract:OBJECTIVE:To review long-term safety data from the rollover study ETV-901, focusing on adverse events (AEs) with a potential nucleos(t)ide association. METHODS:The open-label study ETV-901 (AI463901) assessed the safety of entecavir in chronic hepatitis B patients who received entecavir, lamivudine or adefovir monothe...

    journal_title:Expert opinion on drug safety

    pub_type: 临床试验,杂志文章

    doi:10.1517/14740338.2012.653340

    authors: Manns MP,Akarca US,Chang TT,Sievert W,Yoon SK,Tsai N,Min A,Pangerl A,Beebe S,Yu M,Wongcharatrawee S

    更新日期:2012-05-01 00:00:00

  • Current strategies for managing intestinal failure-associated liver disease.

    abstract::Introduction: Intestinal failure-associated liver disease (IFALD) refers to hepatic dysfunction that results from prolonged parenteral nutrition (PN) use. IFALD is multifactorial in origin and remains a major cause of morbidity and mortality. Prior to 2004, IFALD was associated with mortality as high as 90% in infants...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2021.1867099

    authors: Secor JD,Yu L,Tsikis S,Fligor S,Puder M,Gura KM

    更新日期:2020-12-30 00:00:00

  • Safety of GnRH agonists and antagonists.

    abstract::The widespread application of protocols using gonadotropin-releasing hormone (GnRH) agonists or antagonists in assisted reproduction treatment has led to an increasing number of pregnancies exposed to these drugs. This issue has raised scepticism as to the safety of these medications, concerning both pregnant women an...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.3.1.39

    authors: Tarlatzis BC,Bili H

    更新日期:2004-01-01 00:00:00

  • The safety of pomalidomide for the treatment of multiple myeloma.

    abstract:INTRODUCTION:Pomalidomide, a derivative of thalidomide and member of the immunomodulatory drugs is licenced for use in relapsed and refractory multiple myeloma (RRMM) in Europe, USA, Canada and Japan. AREAS COVERED:This review details all published trials in which pomalidomide has been used in the treatment of myeloma...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2016.1154039

    authors: Jones JR,Pawlyn C,Davies FE,Morgan GJ

    更新日期:2016-01-01 00:00:00

  • Safety of testosterone therapy in men with prostate cancer.

    abstract::Introduction: The use of testosterone therapy (TTh) in men with prostate cancer (PCa) is relatively new, and controversial, due to the longstanding maxim that TTh is contraindicated in men with PCa. Scientific advances have prompted a reevaluation of the potential role for TTh in men with PCa, particularly as TTh has ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2019.1666103

    authors: Morgentaler A,Caliber M

    更新日期:2019-11-01 00:00:00

  • Celecoxib and cardiovascular risks.

    abstract::In a very short time, COX-2 enzyme inhibitors have gone from the darlings to the pariahs of the pharmaceutical industry. These drugs were developed based on the hypothesis whereby selective inhibition of the COX enzyme would lead to reduction in pain and inflammation without associated gastrointestinal and bleeding ri...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.4.6.1005

    authors: Brophy JM

    更新日期:2005-11-01 00:00:00

  • Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.

    abstract:INTRODUCTION:Paliperidone, the major active metabolite of risperidone, is a second-generation antipsychotic that has been developed as an extended-release (ER) oral formulation and a long-acting injectable paliperidone palmitate (PP) formulation. Paliperidone has demonstrated efficacy in the reduction of acute schizoph...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1288716

    authors: Mauri MC,Reggiori A,Paletta S,Di Pace C,Altamura AC

    更新日期:2017-03-01 00:00:00

  • The inhibition of first-pass metabolism of ethanol by H2-receptor antagonists: a tabulated review.

    abstract:INTRODUCTION:In the 1980s-1990s numerous studies were performed on H2-receptor antagonist inhibition of ethanol first-pass metabolism. Blood alcohol concentrations warranting possible driving under the influence citations in the United States have subsequently dropped from ≥100 mg/dL to 50 mg/dL (Utah in 2019) (30 mg/d...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2018.1512969

    authors: Moody DE

    更新日期:2018-09-01 00:00:00

  • Efalizumab.

    abstract:INTRODUCTION:Conventional systemic therapies for psoriasis are associated with serious toxicities that can limit long-term use. In recent years, biological therapies have offered the possibility of long-term therapy with improved safety and efficacy for the treatment of psoriasis. Biological therapies can be classified...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2011.524925

    authors: Talamonti M,Spallone G,Di Stefani A,Costanzo A,Chimenti S

    更新日期:2011-03-01 00:00:00

  • Safety considerations when prescribing immunosuppression medication to pregnant women.

    abstract:INTRODUCTION:In the past two decades, the number of women with autoimmune and inflammatory diseases experiencing a pregnancy has significantly increased in parallel with the enormous advances in the diagnosis and management of these disorders. However, information regarding the safety of immunosuppressive agents comes ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2014.951326

    authors: Gerosa M,Meroni PL,Cimaz R

    更新日期:2014-12-01 00:00:00

  • Cardiovascular effects of anti-diabetes drugs.

    abstract:INTRODUCTION:Cardiovascular disease remains the major contributor to morbidity and mortality in diabetes. From the need to reduce cardiovascular risk in diabetes and to ensure that such risk is not exacerbated by drug treatments, governmental regulators and drug manufacturers have focused on clinical trials evaluating ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2016.1195368

    authors: Younk LM,Lamos EM,Davis SN

    更新日期:2016-09-01 00:00:00

  • Application of botulinum toxin in pregnancy and its impact on female reproductive health.

    abstract::Introduction: Botulinum toxin (BoNT) is a protein secreted by the anaerobic Gram-negative bacterium Clostridium botulinum. Among the seven known subtypes, type A is the most commonly used in women to treat diseases. It primarily blocks presynaptic release of acetylcholine at the neuromuscular junction, resulting in te...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2020.1707803

    authors: Li W,Tang M

    更新日期:2020-01-01 00:00:00

  • Fracture risk associated with chronic use of bisphosphonates: evidence today.

    abstract:IMPORTANCE OF THE FIELD:Bisphosphonates are the most widely used antiresorptive agents for the treatment of osteoporosis. However, the cumulative bisphoshonate exposure and its association with atypical fragility fractures, and the optimum duration of treatment remain obscure. AREAS COVERED IN THIS REVIEW:This review ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2010.517192

    authors: Charopoulos I,Orme S,Giannoudis PV

    更新日期:2011-01-01 00:00:00

  • Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA.

    abstract:BACKGROUND:To perform an international comparison and analysis of celecoxib spontaneous adverse event reports (AERs) from Canada, Australia and the United States, focusing on gastrointestinal, renal and cardiovascular events. This study also examined concomitant medicines use which may have potentiated the risk of the ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2019.1589447

    authors: Baselyous Y,De Cocinis M,Ibrahim M,Kalra A,Yacoub R,Ahmed R

    更新日期:2019-03-01 00:00:00

  • Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.

    abstract::The aim of this manuscript is to report the safety profile of patients treated with ruboxistaurin mesylate (RBX; LY333531), a selective protein kinase C-beta (PKC-beta) inhibitor, for up to 4 years. Data from patients with diabetes (1396 RBX 32 mg/day; 1408 placebo) were combined from 11 placebo-controlled, double-mas...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.5.6.835

    authors: McGill JB,King GL,Berg PH,Price KL,Kles KA,Bastyr EJ,Hyslop DL

    更新日期:2006-11-01 00:00:00

  • Safety evaluation of cephalosporins based on utilization and adverse drug events: analysis of two databases in China.

    abstract:OBJECTIVE:The aim of this study is to evaluate the safety of cephalosporins, based on utilization and adverse drug events (ADEs). METHODS:This is a retrospective study using data on cephalosporins, obtained from Yangtze River hospital drug information and the Wuhan adverse drug reactions monitoring center database, fr...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,多中心研究

    doi:10.1517/14740338.2012.699037

    authors: Ren X,Liu D,Ding N,Huang K,Xiong Y,Du G,Zeng F

    更新日期:2012-09-01 00:00:00

  • The safety and usefulness of low molecular weight heparins and unfractionated heparins in patients with acute stroke.

    abstract::Stroke is a common cause for morbidity and mortality, causing substantial economic costs. Because thrombosis plays a key role in the pathogenesis of ischaemic stroke, heparins, platelet inhibitors and anticoagulants have been used in stroke management. There were high hopes that patients might benefit from the use of ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740330903150157

    authors: Kiphuth IC,Köhrmann M,Huttner HB,Schellinger PD

    更新日期:2009-09-01 00:00:00

  • CGRP inhibitors for migraine prophylaxis: a safety review.

    abstract:INTRODUCTION:Since calcitonin gene-related peptide (CGRP) plays an important role in the pathophysiology of migraine via the activation of the trigeminovascular system, the newest prophylactic treatments directly block CGRP or its receptor. However, the safety of these novel antimigraine drugs is not yet sufficiently e...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1811229

    authors: Rivera-Mancilla E,Villalón CM,MaassenVanDenBrink A

    更新日期:2020-10-01 00:00:00

  • Efficacy and safety of infliximab in psoriatic patients over the age of 65.

    abstract:BACKGROUND:Clinical data on the long-term safety and efficacy of infliximab on psoriatic patients who are older than 65 years are limited. OBJECTIVES:The aim is to report the long-term efficacy, safety and tolerance of infliximab in geriatric patients. METHODS:This was a retrospective study conducted at the Departmen...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2016.1226279

    authors: Chiricozzi A,Pavlidis A,Dattola A,Bianchi L,Chimenti MS,Fida M,Saraceno R

    更新日期:2016-11-01 00:00:00

  • Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.

    abstract:IMPORTANCE OF THE FIELD:Despite the beneficial effect of imatinib treatment in chronic myeloid leukemia patients, some patients develop resistance and/or intolerance and need a switch to second-generation tyrosine kinase inhibitors. Dasatinib is indicated for chronic myeloid leukemia patients with resistance or intoler...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740331003742935

    authors: Breccia M,Alimena G

    更新日期:2010-09-01 00:00:00

  • Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation.

    abstract:INTRODUCTION:Brimonidine tartrate and brinzolamide eye drops are often used as third and fourth line treatment options to reduce intraocular pressure (IOP) in the management of glaucoma and ocular hypertension. Better tolerated, more effective topical agents requiring once daily instillation including prostaglandin ana...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1346083

    authors: Lusthaus JA,Goldberg I

    更新日期:2017-09-01 00:00:00

  • Bleeding complications of unfractionated heparin.

    abstract:INTRODUCTION:Unfractionated heparin is an anticoagulant used in the treatment of myocardial infarction, pulmonary embolism and other thrombotic disorders. However, with anticoagulation comes the risk of bleeding and adverse events. These risks increase with supratherapeutic dosing. AREAS COVERED:In this review, we dis...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2011.521150

    authors: Krishnaswamy A,Lincoff AM,Cannon CP

    更新日期:2011-01-01 00:00:00

  • Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management.

    abstract:INTRODUCTION:The number of HIV patients receiving antiretroviral therapy is increasing worldwide, as new infections continue to occur and access to drugs is scaling up in most developing regions. Due to the efficacious nature of combination antiretroviral therapy in most drug-adherent patients, the concerns on the safe...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2013.806480

    authors: Fernandez-Montero JV,Eugenia E,Barreiro P,Labarga P,Soriano V

    更新日期:2013-09-01 00:00:00

  • Risk of gastrointestinal bleeding during anticoagulant treatment.

    abstract:INTRODUCTION:Gastrointestinal bleeding (GIB) is a major problem in patients on oral anticoagulation therapy. This issue has become even more pressing since the introduction of direct oral anticoagulants (DOACs) in 2009. Areas covered: Here we review current evidence related to GIB associated with oral anticoagulants, f...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1325870

    authors: Lanas-Gimeno A,Lanas A

    更新日期:2017-06-01 00:00:00

  • Prospects for MEK inhibitors for treating cancer.

    abstract:INTRODUCTION:The MAPK pathway is a signaling network that plays a key role in many normal cellular processes and in a large number of human malignancies. One of its effectors, MEK, is essential for the carcinogenesis of different tumors. In recent years, several drugs able to inhibit MEK have been assessed in clinical ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2014.892578

    authors: Martin-Liberal J,Lagares-Tena L,Larkin J

    更新日期:2014-04-01 00:00:00

  • Molecular profiling approaches for identifying novel biomarkers.

    abstract::An unprecedented interest in biomarker development has arisen from the increasing use of genomic information and high-throughput technologies in the field of drug development. Monitoring global cellular responses to perturbation due to disease, drug treatment or toxicity is achieved using molecular profiling methods s...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/eods.3.2.137.27344

    authors: Bailey WJ,Ulrich R

    更新日期:2004-03-01 00:00:00

  • Safety of pembrolizumab in recurrent or advanced gastric cancer expressing PD-L1 refractory to platinum and fluoropyrimidine.

    abstract:INTRODUCTION:Pembrolizumab is a highly selective fully human immunoglobulin 4 monoclonal antibody against programmed death 1 (PD-1). Phase II and III trials have demonstrated that pembrolizumab has antitumor activity in previously treated patients with advanced gastric cancer (AGC). AREA COVERED:Pembrolizumab was appr...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1805428

    authors: Mishima S,Kawazoe A,Shitara K

    更新日期:2020-09-01 00:00:00

  • Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations.

    abstract::A water soluble derivative of camptothecin, irinotecan (CPT-11) is effective against small-cell lung cancer (SCLC), as well as non-SCLC and gastrointestinal cancers. This extended review of recently concluded and ongoing studies focuses on irinotecan in the treatment of limited (LD) and extensive (ED) SCLC specificall...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.5.2.303

    authors: Kawahara M

    更新日期:2006-03-01 00:00:00

  • Hydroxychloroquine in systemic lupus erythematosus (SLE).

    abstract:INTRODUCTION:Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that accumulates in lysosomes where it inhibits some important functions by increasing the pH. HCQ has proved to be effective in a number of autoimmune diseases including systemic lupus erythematosus (SLE). Areas covered: In this review the me...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1269168

    authors: Ponticelli C,Moroni G

    更新日期:2017-03-01 00:00:00

  • Adrenaline in anaphylaxis treatment. Balancing benefits and harms.

    abstract:INTRODUCTION:Although anaphylaxis is a relatively common disorder, clinicians and scientists have debated on how to best define and manage this condition. The current recommendations are focused on the central role of adrenaline, but evidence in support of this therapeutic approach is modest, mainly for the lack of wel...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2016.1167870

    authors: Cervellin G,Sanchis-Gomar F,Lippi G

    更新日期:2016-06-01 00:00:00